1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Drugs In Development, 2022, provides an overview of the Asthma (Respiratory) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Asthma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 14, 48, 61, 11, 138, 48 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 33 and 10 molecules, respectively.
Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Asthma - Overview
- Asthma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Asthma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Asthma - Companies Involved in Therapeutics Development
- Asthma - Drug Profiles
- Asthma - Dormant Projects
- Asthma - Discontinued Products
- Asthma - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Asthma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Asthma - Dormant Projects, 2022
- Asthma - Discontinued Products, 2022
- Number of Products under Development for Asthma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2A Pharma AB
- 3SBio Inc
- 4D Pharma Plc
- AazeinTx Inc
- AB Science SA
- Actinobac Biomed Inc
- Adare Pharma Solutions
- Adial Pharmaceuticals Inc
- Advagene Biopharma Co Ltd
- Aeon Respire Inc
- Airbase Breathing Co LLC
- Akari Therapeutics Plc
- Akeso Inc
- Aldeyra Therapeutics Inc
- Algomedix Inc
- ALK-Abello AS
- Allakos Inc
- AllerGen NCE Inc
- Allergy Therapeutics Plc
- Alveolus Bio Inc
- Alvotech SA
- Amgen Inc
- Amtixbio Co Ltd
- Amytrx Therapeutics Inc
- AnGes Inc
- Antisense Therapeutics Ltd
- Antlia Bioscience Inc
- Apollo Therapeutics LLC
- Aquilon Pharmaceuticals SA
- Areteia Therapeutics Inc
- Argenx SE
- Arrowhead Pharmaceuticals Inc
- ARS Pharmaceuticals Inc
- Artax Biopharma Inc
- Artizan Biosciences Inc
- ASIT Biotech SA
- Aslan Pharmaceuticals Ltd
- AstraZeneca Plc
- Athos Therapeutics Inc
- AtoGen Co Ltd
- Atrapos Therapeutics LLC
- AusBio Ltd
- Avalo Therapeutics Inc
- Bai Shuo Beijing Pharmaceutical Technology Co Ltd
- Bilix Co Ltd
- BioArdis LLC
- Biocon Ltd
- Biohaven Pharmaceutical Holding Company Ltd
- BioMe Inc
- BiosanaPharma BV
- Biosion Inc
- Biotoxtech Co Ltd
- Bioviz Technologies Pvt Ltd
- Boehringer Ingelheim International GmbH
- CALYXHA Biotechnologies GmbH
- Cantex Pharmaceuticals Inc
- Celestial Therapeutics Inc
- Celltrion Inc
- Celon Pharma SA
- Centrymed Pharmaceutical Inc
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chiesi Farmaceutici SpA
- Chronic Airway Therapeutics Ltd
- Clevexel Pharma SA
- Crossject SA
- Crystec Ltd
- CSL Ltd
- CSPC Pharmaceutical Group Ltd
- Cumberland Pharmaceuticals Inc
- Curateq Biologics Pvt Ltd
- Curovir AB
- Cynata Therapeutics Ltd
- Cytokinetics Inc
- Daewoong Pharmaceutical Co Ltd
- Defensin Therapeutics ApS
- Dnarx LLC
- Dragonboat Biopharmaceutical (Shanghai) Co Ltd
- EffectorBio Inc
- EmphyCorp Inc
- Enzychem Lifesciences Corp
- Epsilon Molecular Engineering Inc
- ethris GmbH
- EURRUS Biotech GmbH
- F. Hoffmann-La Roche Ltd
- Fibrotherapeutics Inc
- Foresee Pharmaceuticals Co Ltd
- GeneScience Pharmaceuticals Co Ltd
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- GI Innovation Co Ltd
- Glenmark Pharmaceuticals Ltd
- GliaCure Inc
- GlycoMira Therapeutics Inc
- Gossamer Bio Inc
- GSK plc
- Gurus BioPharm Inc
- Harbour BioMed (Guangzhou) Co Ltd
- HEC Pharma Co Ltd
- Hoth Therapeutics Inc
- Hovione FarmaCiencia SA
- Hunan Jingfeng Pharmaceutical Co Ltd
- iCeutica Inc
- Icure Pharmaceutical Inc
- IGE Therapeutics Inc
- ILiAD Biotechnologies LLC
- ImmuNext Inc
- Immupharma Plc
- Inatherys
- Incannex Healthcare Ltd
- Inmagene Biopharmaceuticals Ltd
- Inmunotek SL
- InnoPharmaScreen Inc
- Innovimmune Biotherapeutics Inc
- InStatin Inc
- Invion Ltd
- Io Therapeutics Inc
- Ionis Pharmaceuticals Inc
- Irex Pharma LLC
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Jiye Biopharmaceutical Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Joincare Pharmaceutical Group Industry Co Ltd
- JW Pharmaceutical Corp
- Kashiv BioSciences LLC
- KBP Biosciences Co Ltd
- KeyMed Biosciences Inc
- Kinaset Therapeutics Inc
- Kissei Pharmaceutical Co Ltd
- Kither Biotech Srl
- KLUS Pharma Inc
- KoBioLabs Inc
- Korea United Pharm Inc
- Kymab Ltd
- Kyowa Kirin Co Ltd
- Landos Biopharma Inc
- Lanier Biotherapeutics Inc
- Laurel Therapeutics
- Lead Discovery Center GmbH
- Lignamed LLC
- Liminal BioSciences Inc
- Longevity Biotech Inc
- Luye Pharma Group Ltd
- Mabpharm Ltd
- Mabtech Ltd
- Mabwell Shanghai Bioscience Co Ltd
- Mariposa Health Ltd
- MD Healthcare Inc
- Mercia Pharma Inc
- Merck & Co Inc
- MitoImmune Therapeutics Inc
- Mitsubishi Tanabe Pharma Corp
- Molecure SA
- Mycenax Biotech Inc
- NAL Pharmaceuticals Ltd
- NeoPharm Co Ltd
- Neovacs SA
- NeuImmune Inc
- Nexeos Bio
- NightHawk Biosciences Inc
- NovaCell Technology Inc
- NovaRock Biotherapeutics Inc
- Novartis AG
- Nuvara Therapeutics LLC
- Oak Hill Bio Inc
- OM Pharma Ltd
- Omeros Corp
- Oneness Biotech Co Ltd
- Opsidio LLC
- Orchid Pharma Ltd
- Orphomed Inc
- Ossium Health Inc
- Palo BioFarma SL
- Pantherics Inc
- Paradigm Biopharmaceuticals Ltd
- Parmedics Inc
- Pfizer Inc
- PharmAbcine Inc
- PharmaKing Co Ltd
- Pharmaxis Ltd
- Principia Biopharma Inc
- Progenra Inc
- Prommune Inc
- Prous Institute for Biomedical Research SA
- PSK Pharma Pvt Ltd
- Pulmatrix Inc
- Pulmokine Inc
- Qu Biologics Inc
- Quench Medical Inc
- Qurient Co Ltd
- RAFT Pharmaceuticals
- RAGE Biotech Pty Ltd
- RAPT Therapeutics Inc
- ReAlta Life Sciences Inc
- Rebus Holdings Inc
- Regeneron Pharmaceuticals Inc
- Respiratorius AB
- Revalesio Corp
- Revolo Biotherapeutics Ltd
- Ribomic Inc
- Ribon Therapeutics Inc
- RS BioTherapeutics Inc
- S-TARget therapeutics GmbH
- Sama Pharm Co Ltd
- Sanofi
- Santhera Pharmaceuticals Holding AG
- Seelos Therapeutics, Inc.
- Shandong Boan Biotechnology Co Ltd
- Shanghai KE Pharmaceutical Co Ltd
- Shanghai Kexin Biotech Co Ltd
- Shanghai Mabgeek Biotechnology Co., Ltd
- Shanghai Meiji Biotechnology Co Ltd
- Shanghai Novamab Biopharmaceuticals Co Ltd
- Shenzhen Forward Pharmaceutical Co Ltd
- Shouyao Holding Co Ltd
- Sichuan Yuanda Shuyang Pharmaceutical Co Ltd
- Siolta Therapeutics Inc
- SolAeroMed Inc
- SpliSense Ltd
- sterna biologicals Gmbh & Co KG
- Suzhou Connect Biopharmaceuticals Ltd
- Suzhou Kanova Biomedical Technology Co Ltd
- Synermore Biologics Co Ltd
- Taiho Pharmaceutical Co Ltd
- TaiwanJ Pharmaceuticals Co Ltd
- TAK-Circulator Corp
- Tarus Therapeutics Inc
- TCF GmbH
- Tetherex Pharmaceuticals Corp
- Tetragenetics Inc
- TFF Pharmaceuticals Inc
- The Geneva Biotech Center SA
- The United Laboratories International Holdings Ltd
- Tianchen Biopharmaceutical (Suzhou) Co Ltd
- Torrent Pharmaceuticals Ltd
- Translational Biosciences
- Transpire Bio Inc
- Trio Medicines Ltd
- United Biomedical Inc
- Upstream Bio Inc
- Vactech Oy
- ValenzaBio Inc
- Vanworld Pharmaceutical (Rugao) Company Ltd
- Vascular BioSciences
- Vasomune Inc
- Vectura Group Plc
- Verona Pharma Plc
- VGSK Technologies Inc
- Vicenna Pharmaceuticals Inc
- Virtici LLC
- Wuhan Healthgen Biotechnology Corp
- YSOPIA Bioscience SA
- Yuhan Corp
- Zhejiang Hisun Pharmaceutical Co Ltd
- Zhengda Tianqing Pharmaceutical Group Co Ltd
